Background
STUDY (ET AL) | Year | Gene | population | Results |
---|---|---|---|---|
Nomani [14] | 2005 | GST | 39 controls 60 patients | Over activity in tumors |
Ebrahimkhani [15] | 2012 | GSTT1 | 100 controls 100 patients | Polymorphism was correlated with CRC risk |
Jamhiri [16] | 2017 | SOD1 | 239 controls 204 patients | Polymorphism was correlated with CRC risk |
Mokarram [19] | 2015 | UBE2Q1 | 50 controls 60 patients | Hyper Methylation |
Mokarram [19] | 2015 | UBE2Q2 | 50 controls 60 patients | Un methylation and stage of tumor |
Amirghofran [22] | 2009 | TGFB1 | 138 controls 134 patients | Polymorphism was correlated with CRC risk |
Damavand [24] | 2015 | SMAD7 | 253 controls 234 patients | Polymorphism was correlated with CRC risk |
Naghibalhossaini [29] | 2012 | AXIN2 | 170 controls 112 patients | Methylation with stage and sex |
Samaei [30] | 2014 | APC, AXIN2, DKK3, SFRP2, 4, 5, WIF1, and WNT5a | 125 N/Ta | Methylation |
Naini [31] | 2016 | SFRP2 | 25 controls 48 polyps | Hyper Methylation as precancerous marker |
Nemati [34] | 2015 | IL-17A | 203 controls 202 patients | Polymorphism was correlated with CRC risk |
Azimzadeh [38] | 2011 | IL-16 | 405 controls 260 patients | Polymorphism was correlated with CRC risk |
Al-Samadi [39] | 2016 | IL-17F | 10 tumors | Under expression in tumors |
Ahangari [42] | 2014 | NOD2 | 88 controls 88 patients | Polymorphism was correlated with CRC risk |
Azimzadeh [43] | 2013 | CD86 | 150 controls 150 patients | Polymorphism was correlated with CRC risk |
Abtahi [44] | 2017 | IL-10 | 30 controls 58 patients | Lower levels in CRC patients |
Habibollahi [49] | 2010 | COX2, iNOS | 17 patients | Correlation with lymph node metastasis |
Hadinia [52] | 2007 | CTLA4 | 190 controls 109 patients | Polymorphism was correlated with CRC risk |
Shafaei [53] | 2013 | CD166 | 121 N/T | Correlation with tumor location |
Mahmoudi [56] | 2016 | ADIPOQ, ADIPOR1 | 339 controls 261 patients | Polymorphism was correlated with CRC risk |
Motlagh [58] | 2007 | EGFR | 34 N/T | Marker of preoperative therapy response |
Tavangar [59] | 2005 | HER2 | 55 N/T | Correlation with tumor size, stage, differentiation |
Orang [61] | 2014 | STYK1/NOK | 40 N/T | Correlation with tumor size, stage |
Tavakoli Koudehi [63] | 2018 | AKAP4 | 62 N/T | Correlation with liver metastasis in CRC patients |
Hamzehzadeh [65] | 2018 | KRAS | 87 patients | Mutation |
Koochak [68] | 2016 | KRAS | 1000 patients | Correlation with age, tumor type |
Omidifar [69] | 2015 | KRAS | 100 patients | Mutation |
Ghavam-Nasiri [71] | 2007 | P53 | 100 patients | Correlation with stage |
Asadi [74] | 2018 | CASPASE3 | 50 N/T | Under expression |
Golmohammadi [75] | 2013 | P53 | 61 patients | Correlation with distal tumors, sex, survival |
Moossavi [77] | 2018 | VDR | 100 controls 100 patients | Polymorphism was correlated with CRC risk |
Mahmoudi [78] | 2010 | VDR | 180 controls 160 patients | Polymorphism was correlated with CRC risk |
Mahmoudi [82] | 2016 | IRS1 | 438 controls 312 patients | Polymorphism was correlated with CRC risk |
Karimi Mazraehshah [86] | 2018 | miR-200c, BMI1 | 38 controls 38 patients | Under an over expression, respectively |
Orang [90] | 2014 | miR-205 | 36 N/T | Correlation with lymph node metastasis, stage |
Basati [91] | 2014 | miR-21 | 40 controls 40 patients | Correlation with stage |
Bastaminejad [92] | 2017 | miR-21 | 40 controls 40 patients | Correlation with stage |
Basati [95] | 2016 | miR-194 | 55 controls 55 patients | Correlation with stage |
Eslamizadeh [105] | 2018 | miR-135b, 20a, 31, 21 | 32 controls 74 patients | Increased levels in CRC patients |
Montazer Haghighi [107] | 2009 | MMR | 248 controls 592 patients | Novel mutations in PMS2 and MLH1 |
Shahmoradi [108] | 2012 | hMLH1 | 20 patients | Novel mutations |
Moghbeli [110] | 2011 | MMR | 67 N/T | MSI was correlated with location, stage, lymph node metastasis |
Faghani [111] | 2012 | MMR | 96 N/T | MSI was correlated with location |
Nazemalhosseini Mojarad [112] | 2016 | MMR | 158 N/T | MSI was correlated with differentiation, stage, sex |
Brim [113] | 2008 | MMR | 53 patients | MSI was correlated with differentiation |
Khatami [114] | 2009 | MGMT | 213 controls 208 patients | Polymorphism was correlated with CRC risk |
Farzanehfar [115] | 2013 | MGMT | 40 N/T | Methylation |
Nemati [117] | 2018 | HDAC3 | 48 N/T | Correlation with stage, differentiation |
Ayoubi [121] | 2017 | H3.3B | 36 N/T | Correlation with stage, lymph node |
Mohammed [125] | 2015 | tRNALeu(CUN) | 100 controls 30 patients | Mutation |
Haghighi [128] | 2008 | MTHFR | 239 controls 227 patients | Polymorphism was correlated with CRC risk |
Naghibalhossaini [131] | 2010 | MTHFR | 231 controls 175 patients | Polymorphism was correlated with CRC risk |
Samanian [136] | 2011 | MDR1 | 60 controls 60 patients | Correlation with grade |
Khedri [137] | 2011 | MDR1 | 137 controls 118 patients | Correlation with stage |
Ardalan Khales [138] | 2015 | SALL4 | 111 N/T | Correlation with grade, depth of invasion |
Raeisossadati [143] | 2014 | DPPA2, HIWI | 46 N/T | Correlation with stage, lymph node metastasis |
Mirzaei [146] | 2015 | LGR5, DCLK1 | 58 controls 58 patients | Correlation with stage |
Niknami [149] | 2017 | FIBRONECTIN | 45 patients | Correlation with grade |
Hosseini [150] | 2018 | NEBL | 67 N/T | Correlation with lymph node metastasis |
Behrouz Sharif [153] | 2016 | SEPT9 | 45 N/T | Methylation |
Raeisossadati [154] | 2011 | CEA, TEM8 | 40 controls 40 patients | Over expression in CRC patients |